--- title: 'Funding Daily Summary: What Happened on October 19, 2026' headline: Nouscom raises €120 million for cancer-prevention vaccine trial description: Estuary Biotherapeutics also launched with $103 million in committed funding for kidney gene therapies. url: https://thebench.bio/news/funding/2026-10-19 topic: funding date: '2026-10-19' covers: - '2026-10-19' date_published: '2026-10-19T12:01:29Z' date_modified: '2026-10-19T12:01:29Z' tags: - Funding - Industry sources: 2 publisher: TheBench.Bio --- # Funding Daily Summary: What Happened on October 19, 2026 **Nouscom raises €120 million for cancer-prevention vaccine trial** Estuary Biotherapeutics also launched with $103 million in committed funding for kidney gene therapies. ## Today in brief Nouscom’s €120 million Series D will support plans for a global trial of NOUS-209, its vaccine for people with Lynch syndrome. [1] Estuary Biotherapeutics debuted with $103 million in committed financing to develop gene therapies for kidney disease. [2] ## Nouscom funds global trial plans for NOUS-209 Nouscom closed an oversubscribed €120 million Series D to advance NOUS-209, a vaccine intended to prevent cancer in people with Lynch syndrome. [1] M Ventures and Revelation Partners co-led the round, joined by Angelini-related investors, the European Investment Bank and Neva SGR. [1] CEO Marina Udier said Nouscom plans to move NOUS-209 into one global registration-enabling trial. [1] Udier said the trial’s primary endpoint will be event-free survival, counting precancerous events and cancer, and that the design has been discussed with the FDA and European Medicines Agency. [1] Long-term findings from a Phase 1b/2 study in people with Lynch syndrome are scheduled for presentation at the ESMO Congress on October 25. [1] Preventive benefit has not yet been demonstrated in a controlled trial. [1] The FDA has granted NOUS-209 Fast Track designation. [1] ## Estuary launches with $103 million for kidney gene therapies Estuary Biotherapeutics launched with $103 million in committed financing, including a $93 million Series A and an earlier $10 million seed round. [2] RA Capital Management led the Series A. Seed investors 4BIO Capital and GV also participated. [2] The company plans to fund clinical proof-of-concept work on EST-101 and EST-201 and advance a platform that delivers adeno-associated virus (AAV) vectors directly to kidney cells. [2] Local delivery is intended to restore polycystin levels across the nephron while avoiding problems associated with systemic AAV delivery. [2] EST-201, an AAV-delivered PKD2 gene therapy, is scheduled to enter clinical development in 2027. [2] EST-101 targets the PC1 functional region for people with PKD1 mutations and is projected to begin clinical testing in 2028. [2] ## The day in numbers - **€120 million**: Nouscom’s Series D financing for NOUS-209. [1] - **$103 million**: Total committed funding behind Estuary Biotherapeutics’ launch. [2] ## Also published - [Fresenius Ventures’ managing director: Europe has the investors. It needs the capital.](), European Biotechnology - [Cancer biotech Nouscom adds €120m, and other financings](), pharmaphorum ## Sources 1. [Nouscom raises €120M to advance cancer prevention vaccine](), European Biotechnology, 2026-10-19 2. [Estuary secures $103m to advance kidney disease gene therapies](), Pharmaceutical Technology, 2026-10-19 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: